Lobular breast cancer with low hormone receptors
Treatments studied
Part of Cancer, Skin clinical trials.
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your cancer is invasive lobular carcinoma, confirmed by a special test
- Your tumor has low hormone receptors (ER and/or PR between 1 and 10 percent) or no hormone receptors (less than 1 percent)
- Your cancer is stage I to III (has not spread far from the breast)
- You had surgery to remove the primary tumor, either before or after chemotherapy
- You were diagnosed between January 2000 and December 2025
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.
This study examines how different imaging scans and blood tests can help doctors better understand the extent of stage IV (advanced) lobular breast cancer. If you have this type of cancer and are starting your first treatment, this trial may help improve how doctors detect and monitor your disease.
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
This trial tests a drug called ivonescimab for people with a specific type of breast cancer called invasive lobular carcinoma that has spread and is no longer responding to hormone therapy or is triple-negative. The goal is to see if it can shrink or slow the cancer.
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
Hear when a new Lobular Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.